Fluconazole Dosing for Candiduria in Renal Disease

Initial Assessment and Treatment Decision

The Infectious Diseases Society of America recommends that asymptomatic candiduria does not require treatment in most patients, even with renal disease, except for high-risk groups such as neutropenic patients, very low birth weight infants, or patients undergoing urologic manipulation 1, 2
Treatment is indicated only for high-risk groups: neutropenic patients, very low birth weight infants, or patients undergoing urologic manipulation, as stated by the Infectious Diseases Society of America 1, 2
Removing the indwelling bladder catheter immediately if present is crucial, as this alone resolves candiduria in nearly 50% of cases, according to the Infectious Diseases Society of America 1, 2

The standard dose for cystitis (lower UTI) is fluconazole 200 mg daily for 2 weeks for fluconazole-susceptible organisms, as recommended by the Infectious Diseases Society of America 1, 3
For hemodialysis patients, the Infectious Diseases Society of America recommends administering 200 mg after each hemodialysis session rather than daily dosing 2
For pyelonephritis (upper UTI), the recommended dose is fluconazole 200-400 mg daily for 2 weeks for fluconazole-susceptible organisms, according to the Infectious Diseases Society of America 1, 3

The choice of antifungal depends critically on the Candida species and susceptibility, with C. albicans and fluconazole-susceptible species being treated with fluconazole, as stated by the Infectious Diseases Society of America 1, 3
C. glabrata (fluconazole-resistant) and C. krusei (intrinsically fluconazole-resistant) require alternative agents, such as amphotericin B deoxycholate or flucytosine, according to the Infectious Diseases Society of America 1, 2, 3

The Infectious Diseases Society of America advises against treating asymptomatic candiduria reflexively, as this leads to unnecessary antifungal exposure and potential resistance development 1, 2
Continuing indwelling catheters during treatment is not recommended, as this significantly reduces cure rates and is the most common cause of treatment failure, according to the Infectious Diseases Society of America 2, 3
The Infectious Diseases Society of America recommends against using standard daily dosing in dialysis patients, as fluconazole must be given after each hemodialysis session to maintain therapeutic levels 2
Assuming all yeast is fluconazole-susceptible is not advisable, as C. glabrata and C. krusei require alternative agents, according to the Infectious Diseases Society of America 1, 2, 3

Verifying species identification and susceptibility testing before finalizing the treatment plan is essential, as empiric fluconazole may fail with resistant species, according to the Infectious Diseases Society of America 2, 3
Monitoring clinical response closely is crucial, and if no improvement is observed, considering repeat cultures to assess for fluconazole resistance, particularly with C. glabrata, is recommended by the Infectious Diseases Society of America 2
Assessing for urinary tract obstruction or fungal balls, which require surgical intervention in addition to antifungal therapy, is necessary, as stated by the Infectious Diseases Society of America 1, 2

In adults with normal renal function and fluconazole‑susceptible isolates, fluconazole 200 mg orally once daily for 14 days is the standard regimen. 4

For fluconazole‑susceptible organisms, fluconazole 200–400 mg orally once daily for 14 days is recommended; a higher dose (400 mg) is preferred in more severe upper‑tract infections. 4
In severe pyelonephritis or when resistance is suspected, adding flucytosine to fluconazole may be considered. 5

Routine antifungal therapy is not indicated for most patients; treatment is reserved for high‑risk groups such as neutropenic patients, very low‑birth‑weight infants (<1500 g), or those undergoing urologic procedures. 5
Immediate removal of indwelling urinary catheters resolves candiduria in approximately 50 % of cases and is the single most important intervention. 5
When treatment is required (e.g., pre‑operative suppression in high‑risk patients), fluconazole 200 mg once daily for 14 days is advised. 5

Fluconazole‑susceptible species (e.g., C. albicans, C. parapsilosis, C. tropicalis): use the standard fluconazole dosing regimens described above.
Fluconazole‑resistant C. glabrata: either amphotericin B deoxycholate 0.3–0.6 mg/kg daily for 1–7 days or oral flucytosine 25 mg/kg four times daily for 7–10 days. 5
Intrinsically resistant C. krusei: amphotericin B deoxycholate 0.3–0.6 mg/kg daily for 1–7 days. 5

Lipid formulations of amphotericin B should not be used for urinary tract infection because they achieve lower urinary concentrations due to reduced renal excretion. 6

In the presence of fungal balls or obstructive uropathy, surgical removal of the obstruction is required in addition to antifungal therapy; medical therapy alone is unlikely to succeed. 5